University of Massachusetts Center for Clinical and Translational Science

我们已经建立了马萨诸塞大学临床和翻译科学中心 (UMCCTS)，包括五个加州大学马萨诸塞州分校。在运作上，该中心位于大学的 伍斯特校区，由医学院管理。该中心是中国的学术之家 马萨诸塞州大学所有校区的临床和转化型科学家。CTSA计划将建立临床和 以世界级基础科学为基础的翻译研究--获奖证明 2006年诺贝尔生理学或医学奖授予克雷格·梅洛，阿尔伯特·拉斯克奖授予维克托·安布罗斯 在2008年。UMCCTS的目标是：1)通过招聘以下人员来加速早期翻译研究 优秀的T1研究带头人；建立创新的研究核心设施；开发新的 基于UBulk发现的治疗、设备和干预；2)整合独特的临床网络 在新英格兰中部和马萨诸塞州建立和扩大研究和医疗保健服务 T2(临床有效性研究)和T3(实施和传播研究)能力 招募优秀的T2和T3研究领导者，并开发创新的T2/T3核心设施；以及 加强患者和社区对临床/人群研究的推广和参与；3) UMCCTS将与UMASS系统的所有校园和学校合作开发 促进临床和转化性研究职业发展的项目、课程和教师支持系统。 州长德瓦尔·帕特里克和马萨诸塞州议会最近通过了一项立法，承诺提供10亿美元 国家投资将直接用于英联邦的生命科学。带着9000万美元的种子 在资助下，该大学建立了UMASS先进治疗集群(UMATC)，其中包括 RNA治疗研究所，干细胞生物学和再生医学中心，以及基因 治疗中心。UMATC加入了马萨诸塞州生物实验室、迈耶斯初级保健研究所、 和英联邦医学，四个在学术中心很少找到的创新组成部分，以 在临床和转化性研究中，加快从工作台到床边到社区的发现。 相关性(请参阅说明)： 马萨诸塞大学临床与翻译科学中心(UMCCTS)将改变 开展临床和转化性研究，为所有大学临床提供一个“学术之家” 调查人员。UMCCTS将提供强有力的试点资助计划、全面的教育和职业生涯 开发计划和创新的核心设施，以支持和培养临床研究人员。

We have established the University of Massachusetts Center for Clinical and Translational Science (UMCCTS) which includes the five UMass campuses. Operationally, the Center is located at the University's Worcester campus and managed by the School of Medicine. The Center serves as the "academic home" for clinical and translational scientists across all UMass campuses. The CTSA program will build clinical and translational research upon a foundation of world class basic science as evidenced by the award of the Nobel Prize in Physiology or Medicine to Craig Mello in 2006 and the Albert Lasker Award to Victor Ambros in 2008. The UMCCTS aims are to: 1) Accelerate early phase translational (Tl) studies by recruiting outstanding T1 research leaders; establishing innovative research core facilities; and developing new therapies, devices, and interventions based upon UMass discoveries; 2) Integrate unique networks of clinical research and healthcare delivery in Central New England and Massachusetts at-large to build and expand T2 (clinical effectiveness research) and T3 (implementation and dissemination research) capacity by recruiting outstanding T2 and T3 research leaders, and by developing innovative T2/T3 core facilities; and enhancing patient and community outreach and participation in clinical/population-based research; 3) The UMCCTS will work collaboratively with all campuses and schools ofthe UMass system in developing programs, curricula, and faculty support systems that promote careers in clinical and translational research. Governor Deval Patrick and the Massachusetts Legislature recently enacted legislation committing $1 billion in state investment to be directed to the Life Sciences in the Commonwealth. With $90 million in seed funding, the University has established the UMass Advanced Therapeutics Cluster (UMATC) which includes the RNA Therapeutics Institute, the Center for Stem Cell Biology and Regenerative Medicine, and the Gene Therapy Center. The UMATC joins the Massachusetts Biologic Laboratories, Meyers Primary Care Institute, and Commonwealth Medicine, four innovative components that are rarely found in academic centers, to speed bench to bedside to community discoveries in clinical and translational research. RELEVANCE (See instructions): The University of Massachusetts Center for Clinical and Translational Science (UMCCTS) will transform the conduct of clinical and translational research by providing an "academic home" for all university clinical investigators. The UMCCTS will provide robust pilot grant programs, comprehensive education and career development programs, and innovative core facilities to support and nurture clinical investigators.